5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Brief description of study

The purpose of this double-blind randomized study is to explore the efficacy of psilocybin (5-HT2A receptor agonist psilocybin) as a smoking cessation treatment. In this study participants will be randomized to receive either:

  1. psilocybin; 30 mg in session 1 and either 30 or 40 mg in session 2, with sessions 1 week apart; or
  2. niacin; 100 mg in session 1 and either 100 mg or 200 mg in session 2, with sessions 1 week apart

Cognitive behavior therapy (CBT) will be administered to both groups and will allow us to test psilocybin’s efficacy above and beyond an established treatment approach. The total study duration will be approximately 12 months after screening and enrollment, and include roughly 14 in-person visits for screening, study intervention, psilocybin sessions, and follow-up meetings.


Clinical Study Identifier: s22-00503
ClinicalTrials.gov Identifier: NCT05452772
Principal Investigator: Michael P. Bogenschutz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.